becton dickinson compani
bdx revenu growth street expect due
paclitaxel headwind small inventori adjust medic deliveri
broad portfolio remain healthi still expect grow revenu
full year grow first half account flu headwind
need drive close increment organ growth back
half year versu first half year despit addit head wind
drug coat balloon probabl gener versu assumpt
regard back half year point share gain medic
manag expect strong growth bd time instrument
sale reagent expect benefit life scienc well recent launch
sever new product past quarter bd intervent covera stent graft
fistula indic venovo larg diamet venou stent wavelinq endovascular
av fistula system expect addit product launch addit
seen much benefit bard revenu synergi yet expect synergi
build second half typic season stronger
fda continu commun compani on-going paclitaxel
base clinic trial regulatori file indic fda
shut everyth relat paclitaxel result think fda panel
end wors expect think fda continu recommend paclitaxel
least difficult case short see downsid
cut alreadi taken believ remain confid
revenu growth outlook long term regardless happen fda panel
littl ep upsid due elimin gore
royalti better revenu growth back half help drive
higher adjust model result maintain buy rate
base attract valuat outlook
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
becton dickinson compani
becton dickinson co bd diversifi global
medic technolog compani produc
medic devic instrument system reagent
healthcar life scienc research clinic
diagnost pharmaceut market bd
grown larg medic conglomer
significantli expand compani medic
technolog footprint infus medic
well regard provid medic
suppli diagnost life scienc tool
seri growth profit initi
result better organ sale ep growth
led multipl expans acquisit
carefus bard provid
unmatch portfolio new growth
plu organ revenu growth
becton dickinson compani may
becton dickinson compani
price object base ep estim multipl
slight premium med-tech averag think premium warrant given
averag ep growth opportun acceler revenu
group averag well especi revenu synergi cr bard acquisit
downsid risk po failur success integr cr bard acquisit
increas competit slower growth emerg market price eros lower
healthcar util trend soft uptak new diagnost product slower growth
hospit capit spend
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
becton dickinson compani may
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
becton dickinson compani may
